ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 30, 2022 12:42 JST
Source:
Tianda Pharmaceuticals Limited
天大药业2022全年业绩
业务高质量发展
加强创新研发、加大业务拓展力度
派发末期和特别股息回馈股东
香港, Jun 30, 2022 - (ACN Newswire) - 天大药业有限公司 (天大药业或本集团 ,股份代号 :0455.HK) 欣然宣布截至2022年3月31日止全年业绩。报告期内,本集团整体业务取得较好发展,收入5亿1,000万港元,同比增长7.5% 。创新和研发工作稳步推进, 研发费用1,590万港元,同比增长34.7%。本集团财务状况稳健,于2022年3月31日现金和现金等价物为3亿3,400万港元,具充足财务资源支持业务发展。为庆祝本集团更名为「天大药业有限公司」10周年,董事会建议派发末期股息每股0.26港仙和特别股息每股0.56港仙,回馈股东长期的支持和信赖。
位于珠海金湾的新研发及制药基地
药物和医疗科技业务收入3亿9,610万港元,同比增长10.7%。药物和医疗科技业务重点关注产品和技术,积极引进、研发、倂购创新药、健康产品和医疗器械,聚焦心脑血管、妇儿、呼吸系统、肿瘤、康复等重点领域。本集团主要产品心脑血管用药托平®缬沙坦胶囊在中国市场同类产品中销量第一,凭借在国家第三批集中带量采购第一顺位中标,放量增长,扩大品牌影响力。通过销售团队和渠道的整合, 本集团药品尤其是儿科用药托恩®布洛芬混悬液和布洛芬混悬滴剂取得满意的销售增长。位于珠海金湾的新研发及制药基地已顺利投产,第一期投资金额4.3亿港元,配置进口和国产最新型自动化设备,立足创新发展,加快丰富产品线和提高产能,已成功签订5个CDMO/CMO合同,锐意成为一个高标准、高质量、高效能的医药健康产业基地。
中医药业务收入1亿650万港元,同比减少4.9%。报告期首9个月,中医药业务实现较快增长,运用多种方式实现和药农、合作社、经销商、药企等伙伴的互惠合作,构建面向全国全球的中药材业务网络。未来,将以品种为中心,重点发展中药材国内外贸易,中药饮片、配方颗粒生产销售及配送业务,整合产业上下游优质资源。
医疗和保健服务收入740万港元,同比增长57.4%。本集团稳健推进新型中医馆「天大馆」拓展,自建、加盟和并购并举,优先开拓粤港澳大湾区,兼顾全国全球布局。自2019年起先后在珠海、香港和悉尼三地不同的中医药管理法规下开馆,打造全球连锁运营模式, 其中珠海天大馆成为全球首家获ISO 9001:2015质量管理体系认证和Qualicert国际服务认证的中医馆。本集团关注民众健康及积极履行企业社会责任,在2022年初第五波新冠疫情袭击香港期间,本集团依托「云上天大馆」推出「天大馆全球中医云端科技抗疫平台」,开展「赠医施药 同心抗疫」公益大行动,为民众提供从预防、治疗到康复的全方位远程中医医疗服务,并推出新冠后遗症中医调理服务。
国家「十四五」规划提出全面推进健康中国建设,把保障人民健康放在优先发展的战略位置,为人民提供全方位全生命期健康服务。本集团秉承「您的健康是天大的事!」这一使命,贯彻「以发展中医药产业为基础,发展创新药物和医疗科技,发展优质医疗和保健服务」战略,实施「3D+1S」重大举措 (业务拓展BD、研究开发R&D、投资发展ID、市场销售S),联动并举,通过外部引进、研发、倂购等方式,不断丰富产品线和提高管线内研发项目的质量和数量,并在全球范围内洽寻前沿技术和产品以及优质项目,努力实现高质量发展,为守护人类健康做出更大贡献。
有关天大药业有限公司
天大药业有限公司(香港联交所上市公司,股份代号0455.HK)以发展中医药产业为基础,发展创新药物和医疗科技,发展优质医疗和保健服务,致力发展成为立足中国,辐射全球的领先医药企业。
新闻查询
天大药业有限公司
投资者关系部
电话:+852 2545 3313
电邮:
ir@tianda.com
Source: Tianda Pharmaceuticals Limited
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
More Latest Release >>
Related Release
Tianda Pharma Announces 2022/23 Interim Results
November 25 2022 23:54 JST
Tianda Pharmaceuticals Annual Results 2022
June 30 2022 11:40 JST
Tianda Pharma Interim Results 2021
November 26 2021 18:40 JST
The third TDMall in the world opened in Sydney, Australia
March 16 2021 19:52 JST
Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout
March 04 2021 19:43 JST
Tianda Pharmaceuticals acquired and established a long-term relationship of Cooperation with Yeung & Young Medicare and Qi's Living
October 06 2020 11:00 JST
HK Main-Board Listed Tianda Pharmaceuticals (00455.HK) Promising Outlook for Growth
July 10 2020 15:26 JST
More Press release >>